drugset / Trial / NCT00937157

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

NCT00937157

NaSingle-groupOpen-labelDiagnostic

Summary

This study will: * Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol. * Compare whether the decrease in the cumulative number of Gd-enhancing lesions significantly differs between pre-treatment (day 0) and post-treatment (12 months) using 1.5T standard and 3T optimized protocols. * Investigate the correlation between MTR and the cumulative number and volume of Gd enhancing lesions on 1.5T standard and 3T optimized protocols in patients treated with GA. This study suggests that GA may favorably affect early events in lesion formation, in addition to exerting more transient beneficial effects on established areas of inflammation and demyelination, and that this effect may be observed only with the 3T optimized protocol.

Timeline

Start
2007-09
Primary completion
2010-07
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Glatiramer Acetate Small molecule 20 mg Subcutaneous

Indications